Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO103 Vaccination in High Risk Smoldering Multiple Myeloma
NCT03850522Phase 2Terminated
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IO103 + Montanide in smoldering multiple myeloma (SMM). Primary endpoint: Overall Response Rate at 26 weeks. Started Feb 2019; status: terminated.
02
Drugs
IO103 + Montanide
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03850522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850522.